Leland Gershell
Stock Analyst at Oppenheimer
(4.47)
# 265
Out of 5,182 analysts
159
Total ratings
47.33%
Success rate
28.45%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Outperform | $1,060 → $1,014 | $785.07 | +29.16% | 8 | Apr 2, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $110 → $80 | $52.60 | +52.09% | 10 | Mar 18, 2026 | |
| ENGN enGene Holdings | Maintains: Outperform | $33 → $30 | $7.31 | +310.40% | 4 | Mar 11, 2026 | |
| OCGN Ocugen | Initiates: Outperform | $10 | $1.86 | +437.63% | 1 | Mar 11, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $125 → $145 | $87.48 | +65.75% | 3 | Mar 9, 2026 | |
| CALC CalciMedica | Maintains: Outperform | $20 → $10 | $0.62 | +1,505.14% | 6 | Mar 5, 2026 | |
| AARD Aardvark Therapeutics | Maintains: Outperform | $35 → $21 | $3.93 | +434.35% | 2 | Mar 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $98 → $95 | $57.20 | +66.08% | 4 | Feb 24, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $246 → $262 | $233.20 | +12.35% | 13 | Feb 12, 2026 | |
| SPRB Spruce Biosciences | Initiates: Outperform | $283 | $63.65 | +344.62% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $54 | $31.60 | +70.89% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $24 | $13.07 | +83.63% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $5.92 | +204.05% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $14.47 | +148.79% | 7 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $73 → $87 | $39.96 | +117.72% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $30.06 | +166.13% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $74.14 | -17.72% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $327.25 | +49.73% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $6.44 | +210.56% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $85.48 | +28.69% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $19.10 | +62.30% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $7.10 | +40.85% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $0.18 | +5,361.50% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $208.09 | -29.36% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.56 | +1,855.42% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $24.73 | +114.31% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.73 | +221.72% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $1.90 | +263,057.89% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.22 | +378.93% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $25.31 | +14.58% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $14.41 | +142.89% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.27 | +3,552.30% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.99 | +1,920.20% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.78 | +630.34% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $4.05 | +2,862.96% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.40 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $30.52 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.67 | - | 5 | Mar 31, 2020 |
argenx SE
Apr 2, 2026
Maintains: Outperform
Price Target: $1,060 → $1,014
Current: $785.07
Upside: +29.16%
Soleno Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $110 → $80
Current: $52.60
Upside: +52.09%
enGene Holdings
Mar 11, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $7.31
Upside: +310.40%
Ocugen
Mar 11, 2026
Initiates: Outperform
Price Target: $10
Current: $1.86
Upside: +437.63%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Outperform
Price Target: $125 → $145
Current: $87.48
Upside: +65.75%
CalciMedica
Mar 5, 2026
Maintains: Outperform
Price Target: $20 → $10
Current: $0.62
Upside: +1,505.14%
Aardvark Therapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $35 → $21
Current: $3.93
Upside: +434.35%
BioMarin Pharmaceutical
Feb 24, 2026
Maintains: Outperform
Price Target: $98 → $95
Current: $57.20
Upside: +66.08%
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $246 → $262
Current: $233.20
Upside: +12.35%
Spruce Biosciences
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $63.65
Upside: +344.62%
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $31.60
Upside: +70.89%
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $13.07
Upside: +83.63%
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $5.92
Upside: +204.05%
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $14.47
Upside: +148.79%
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $39.96
Upside: +117.72%
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $30.06
Upside: +166.13%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $74.14
Upside: -17.72%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $327.25
Upside: +49.73%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $6.44
Upside: +210.56%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $85.48
Upside: +28.69%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $19.10
Upside: +62.30%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $7.10
Upside: +40.85%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $0.18
Upside: +5,361.50%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $208.09
Upside: -29.36%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.56
Upside: +1,855.42%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $24.73
Upside: +114.31%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.73
Upside: +221.72%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $1.90
Upside: +263,057.89%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.22
Upside: +378.93%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $25.31
Upside: +14.58%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $14.41
Upside: +142.89%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.27
Upside: +3,552.30%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.99
Upside: +1,920.20%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.78
Upside: +630.34%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $4.05
Upside: +2,862.96%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.40
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $30.52
Upside: -
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.67
Upside: -